Postgraduate Medical Journal (March 1981) 57, 150–152

Relationships of the platelet aggregate ratio to serum cholesterol concentration, smoking and age

JAMES W. DAVIS
M.D., F.A.C.P.

H. DANIEL LEWIS JR
M.D., F.A.C.P.

PHYLLIS E. PHILLIPS

REBECCA F. DAVIS

Veterans Administration Medical Center, Kansas City, Missouri, and the Department of Medicine,
University of Kansas School of Medicine, Kansas City, Kansas

Summary
The platelet aggregate ratio has been found to be decreased in some patients with vascular diseases suggesting the presence of increased circulating platelet aggregates. It has also been reported that hypercholesterolaemia is associated with an enhanced response of platelets to aggregating agents in platelet-rich plasma. The primary purpose of this investigation was to determine correlation of the platelet aggregate ratio with the serum cholesterol concentration of men with vascular diseases. For 52 men referred because of known or suspected coronary artery disease, cerebrovascular disease, or venous thromboembolism, the correlation coefficient of 0·66 suggested that the serum cholesterol concentration within the range observed (135–360 mg/dl) was not a factor influencing the platelet aggregate ratio. There was not a statistically significant difference between the mean platelet aggregate ratios or the mean serum cholesterol concentrations of the 21 non-smokers and the 31 smokers studied. A correlation coefficient of 0·03 between the platelet aggregate ratio and age of the patient suggested that the platelet aggregate ratio was independent of age in men with occlusive vascular diseases.

Introduction
Wu and his colleagues described the platelet aggregate ratio as an index of circulating platelet aggregates and reported it to be decreased in some patients with occlusive vascular diseases (Wu and Hoak, 1974, 1975; Wu, Barnes and Hoak, 1976). Their method is based on the ratio of the platelet count of platelet-rich plasma prepared from blood mixed with a solution of EDTA and formaldehyde to that of platelet-rich plasma prepared in the same manner except for the absence of formaldehyde. They theorized that any platelet aggregates present in blood would be fixed when withdrawn into a solution containing formaldehyde and EDTA and break apart when withdrawn into a solution containing EDTA without formaldehyde. If platelet aggregates were present in blood, the platelet count should be lower in the platelet-rich plasma containing formaldehyde because platelet aggregates would be spun down with erythrocytes. The observation of Wu and Hoak (1974) that the platelet aggregate ratio of rabbits decreased after the i.v. infusion of thrombin, suggested that this ratio monitored the presence of platelet aggregates circulating in vivo. However, Rohrer et al. (1978a) found that the platelet aggregate ratio of normal human venous blood samples varied with the rate of blood flow into the needle, suggesting that platelet aggregates formed in the needle and tubing may affect the platelet aggregate ratio. Subsequently, the platelet aggregate ratio was reported to be highly correlated with β-thromboglobulin (Chen et al., 1979) and to decrease in association with an increase in the plasma concentration of platelet factor 4 after exhaustive exercise (Levine et al., 1979). This suggests a relationship of the platelet aggregate ratio to secretion of the contents of α-granules from platelets (Kaplan et al., 1979). The observation in patients with ischaemic heart disease of a high correlation between the platelet aggregate ratio and the platelet half-life in vivo is evidence supporting the interpretation of the platelet aggregate ratio as an index of circulating platelet aggregates in such patients (Salem, Koutts and Firkin, 1980).

The authors reviewed the records of men with vascular disease whose platelet aggregate ratios had been determined in their laboratory to learn if the
values were related to their serum cholesterol concentration, to whether or not they smoked tobacco or to their age.

**Patients and methods**

The subjects of this investigation were 52 men ranging in age from 33 to 86 years (mean age, 56 years) whose platelet aggregate ratios were determined in the laboratory after referral because of known or suspected coronary artery disease, cerebrovascular disease or venous thromboembolism. They had not taken anticoagulants, anti-inflammatory agents, diazepam, dipyriramole, phenothiazines or tricyclic antidepressants during the week before testing the platelet aggregate ratio. Fasting serum cholesterol values, dated within 3 months of the platelet aggregate ratio, were obtained from the hospital records after determination in the clinical chemistry laboratory by an automated enzymatic technique.

Platelet aggregate ratios were determined essentially as described by Wu (1978). A first sample of antecubital venous blood was drawn into a plastic syringe containing a buffered solution of EDTA and formaldehyde and a second sample into another syringe containing a buffered solution of EDTA without formaldehyde. The contents of the syringes were immediately mixed by inverting 3 times, then transferred to siliconized glass tubes and incubated at room temperature for 15 min before centrifugation at 220 g (bottom of tube) for 8 min. The supernatants were diluted 1:20 in 1% ammonium oxalate for platelet counting by phase-contrast microscopy using duplicate pipettes. The ratio of the platelet count in the supernatant containing formaldehyde to that without formaldehyde was calculated.

The significance of the differences between mean platelet aggregate ratios and mean serum cholesterol concentrations was determined by the Wilcoxon rank sum test. The Spearman rank correlation coefficient was used to determine the association of the platelet aggregate ratio with age and serum cholesterol concentration.

**Results**

The fasting serum cholesterol concentrations of the 52 patients studied ranged from 135 to 360 mg/dl. The mean platelet aggregate ratios (± s.d.) of the 26 men with the lowest serum cholesterol concentrations (135–225 mg/dl) and of the 26 men with the highest serum cholesterol concentrations (230–360 mg/dl) were 0.79 ± 0.17 and 0.78 ± 0.13 respectively (P > 0.1). The platelet aggregate ratio correlated poorly with the fasting serum cholesterol concentration (r = 0.06; P = 0.7) and with the age (r = 0.03; P > 0.9) of the 52 men.

The subjects included 31 habitual smokers of tobacco products (mostly cigarettes) and 21 non-smokers. The mean platelet aggregate ratio (± s.d.) of the smokers was 0.76 ± 0.16 and of the non-smokers was 0.81 ± 0.14 (P > 0.1). The mean fasting serum cholesterol (± s.d.) of the 31 smokers (whose mean age was 55 years) was 227 ± 52 mg/dl and of the 21 non-smokers (whose mean age was 58 years) was 243 ± 52 mg/dl (P > 0.1).

**Discussion**

It has been reported (Carvalho, Colman and Lees, 1974) that the platelets of patients with type II hyperlipoproteinaemia and a mean serum cholesterol concentration of 354 mg/dl had an enhanced aggregation response to epinephrine, ADP or collagen in platelet-rich plasma. Although Wu et al. (1975) described increased circulating platelet aggregates in Rhesus monkeys with experimentally-induced hypercholesterolaemia, they found a poor correlation between the platelet aggregate ratio and the serum cholesterol concentration. The low correlation coefficient (0.06) between the platelet aggregate ratio and the serum cholesterol concentration of the present patients suggests that the serum cholesterol concentration within the range observed (135–360 mg/dl) is not a major factor influencing the platelet aggregate ratio in man.

Although in 2 studies before 1960 (Thomas, 1958; Karvonen et al., 1959) men who smoked tobacco had higher serum concentrations of total cholesterol than did non-smokers, results are in agreement with those of 2 more recent studies (Pozner and Billimoria, 1970; Enger et al., 1977) which showed the mean serum cholesterol concentration of male smokers to be no higher than that of non-smokers.

Eriksson, Hellem and Stormorken (1977) found a small but highly statistically significant increase in 'platelet adhesiveness' in smokers as compared with non-smokers when the former were tested at least 12 hr after the last cigarette was smoked. After finding that the mean platelet aggregate ratios of 2 groups of healthy volunteers decreased during a 20-min period in which 2 cigarettes were smoked (Davis and Davis, 1979, 1980), the authors analysed the present series of 52 men to see whether the 31 habitual smokers had lower ratios than did the 21 non-smokers. This was found to be the case, but the difference was not statistically significant. Rohrer et al. (1978b) found a lower mean platelet aggregate ratio in normal smokers than in normal non-smokers, but the difference also was not statistically significant. The possibility of a prolonged effect of smoking on the platelet aggregate ratio is more strongly suggested by the mean platelet aggregate ratios of 20 healthy habitual smokers and 20 healthy non-smokers of similar age and sex distribution. The mean platelet aggregate ratio of the
smokers, who were asked to abstain from smoking for at least 8 hr before determination of the platelet aggregate ratio, was 0.79 and of the non-smokers (Davis and Davis, 1980) was 0.91 (P<0.05). The platelet aggregate ratios of patients with a variety of thromboembolic conditions have been reported to be low by most workers (Wu and Hoak, 1974, 1975; Wu et al., 1976; Gjasdal, 1976; Dougherty, Levy and Weksler, 1977; Guyton and Willerson, 1977; Wu, 1978; Mehta and Mehta, 1979; Salem et al., 1980) and normal by others (Prazich et al., 1977; Rohrer et al., 1978b). A lowered platelet aggregate ratio associated with the vascular diseases of the patients in this study may have tended to obscure a chronic effect of tobacco smoking on their ratios.

Acknowledgment

This study was supported by the Veterans Administration.

References


Relationships of the platelet aggregate ratio to serum cholesterol concentration, smoking and age

James W. Davis, H. Daniel Lewis, Jr, Phyllis E. Phillips and Rebecca F. Davis

*Postgrad Med J* 1981 57: 150-152
doi: 10.1136/pgmj.57.665.150

Updated information and services can be found at:
http://pmj.bmj.com/content/57/665/150

<table>
<thead>
<tr>
<th>Email alerting service</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.</td>
</tr>
</tbody>
</table>

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/